These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
517 related articles for article (PubMed ID: 28697282)
1. Exploring the potential of natural and synthetic neuroprotective steroids against neurodegenerative disorders: A literature review. Bansal R; Singh R Med Res Rev; 2018 Jul; 38(4):1126-1158. PubMed ID: 28697282 [TBL] [Abstract][Full Text] [Related]
2. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. Dhib-Jalbut S; Arnold DL; Cleveland DW; Fisher M; Friedlander RM; Mouradian MM; Przedborski S; Trapp BD; Wyss-Coray T; Yong VW J Neuroimmunol; 2006 Jul; 176(1-2):198-215. PubMed ID: 16983747 [TBL] [Abstract][Full Text] [Related]
3. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. Dunkel P; Chai CL; Sperlágh B; Huleatt PB; Mátyus P Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814 [TBL] [Abstract][Full Text] [Related]
4. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides. Singh K; Gupta JK; Kumar S; Soni U Curr Protein Pept Sci; 2024; 25(7):507-526. PubMed ID: 38561605 [TBL] [Abstract][Full Text] [Related]
5. Flavonoid-based therapies in the early management of neurodegenerative diseases. Solanki I; Parihar P; Mansuri ML; Parihar MS Adv Nutr; 2015 Jan; 6(1):64-72. PubMed ID: 25593144 [TBL] [Abstract][Full Text] [Related]
7. Neuroprotection of Coenzyme Q10 in Neurodegenerative Diseases. Yang X; Zhang Y; Xu H; Luo X; Yu J; Liu J; Chang RC Curr Top Med Chem; 2016; 16(8):858-66. PubMed ID: 26311425 [TBL] [Abstract][Full Text] [Related]
8. Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases. Pérez-Olives C; Rivas-Santisteban R; Lillo J; Navarro G; Franco R Adv Exp Med Biol; 2021; 1264():81-92. PubMed ID: 33332005 [TBL] [Abstract][Full Text] [Related]
9. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies. Chen JF; Chern Y Handb Exp Pharmacol; 2011; (200):267-310. PubMed ID: 20859800 [TBL] [Abstract][Full Text] [Related]
10. Neuroprotection by saponins. Sun A; Xu X; Lin J; Cui X; Xu R Phytother Res; 2015 Feb; 29(2):187-200. PubMed ID: 25408503 [TBL] [Abstract][Full Text] [Related]
11. Neurodegeneration by oxidative stress: a review on prospective use of small molecules for neuroprotection. Singh E; Devasahayam G Mol Biol Rep; 2020 Apr; 47(4):3133-3140. PubMed ID: 32162127 [TBL] [Abstract][Full Text] [Related]
12. New therapeutic strategy for Parkinson's and Alzheimer's disease. Esposito E; Cuzzocrea S Curr Med Chem; 2010; 17(25):2764-74. PubMed ID: 20586718 [TBL] [Abstract][Full Text] [Related]
13. Kaempferol, a potential neuroprotective agent in neurodegenerative diseases: From chemistry to medicine. Jin S; Zhang L; Wang L Biomed Pharmacother; 2023 Sep; 165():115215. PubMed ID: 37494786 [TBL] [Abstract][Full Text] [Related]
15. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. Youdim MB; Fridkin M; Zheng H J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846 [TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma. Kempuraj D; Thangavel R; Kempuraj DD; Ahmed ME; Selvakumar GP; Raikwar SP; Zaheer SA; Iyer SS; Govindarajan R; Chandrasekaran PN; Zaheer A Biofactors; 2021 Mar; 47(2):190-197. PubMed ID: 33098588 [TBL] [Abstract][Full Text] [Related]
17. Mitochondrial Dysfunctions: A Red Thread across Neurodegenerative Diseases. Stanga S; Caretto A; Boido M; Vercelli A Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466216 [TBL] [Abstract][Full Text] [Related]
18. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. Tan L; Yu JT; Tan L J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820 [TBL] [Abstract][Full Text] [Related]
19. [Clinical pharmacology and therapeutic aspects in certain degenerative neurological diseases]. Maloteaux JM Bull Mem Acad R Med Belg; 1996; 151(10-11):429-32; discussion 432-4. PubMed ID: 9491620 [TBL] [Abstract][Full Text] [Related]
20. PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease. Corona JC; Duchen MR Free Radic Biol Med; 2016 Nov; 100():153-163. PubMed ID: 27352979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]